fbpx

Exclusive A.I. Mortality Model

Revolutionizing End-of-Life Care with Proven AI Technology

Patent Pending

Our Exclusive A.I. Mortality Model, in use for the past three years at an ADCC cancer center, is transforming how patients, providers, health systems, and payors approach end-of-life care. This advanced model leverages cutting-edge machine learning to predict 90-day mortality with remarkable accuracy, offering invaluable insights and fostering better decision-making for all stakeholders.

Key Benefits

For Providers and Health Systems:

  • Enhanced Predictive Accuracy: Our AI model outperforms specialized oncologists in predicting near-term death, enabling more precise and timely interventions.
  • Value-Based Discussions: Trigger meaningful, value-based discussions with patients, ensuring care aligns with their preferences and improving the quality of end-of-life care.
  • Clinical Decision Support: Integrate our AI model with existing clinical workflows to support decision-making and re-evaluation of therapy, ultimately improving patient survival rates.

      For Patients:

      • Informed Choices: Empower patients with critical information to make better choices about their care at the end of life, aligning treatments with their values and wishes.
      • Improved Quality of Life: Facilitate discussions about palliative care options, enhancing the overall quality of life during the final stages of illness.

      For Payors:

      • Cost Efficiency: Utilize our AI model to streamline care processes, reducing unnecessary interventions and hospitalizations and ultimately lowering costs per member per month.
      • Quality Assurance: Ensure high-quality, patient-centered care that meets regulatory standards and supports positive outcomes.

      Market Reach

       

      Our target market includes the Alliance of Dedicated Cancer Centers (ADCC), comprising 11 leading cancer centers, and the 71 National Cancer Institute (NCI) designated cancer centers. The demand for high-quality predictive models is growing, and multiple cancer centers are already showing interest in our proven AI technology.

      AI Model Future Releases

      1. Expand Time Points: Extend predictive capabilities up to 18 months.
      2. Broaden Disease Insights: Apply serious illness insights to other major diseases, including heart failure, dementia, and renal disease.

      1. Diversify Data Sets: Enhance model types and data sets, incorporating claims data for more comprehensive analysis.
      2. Regulatory Approval: Seek FDA clearance and New Technology Add-on Payment (NTAP) for wider adoption and integration.

      Clinical Decision Support

      We are committed to extending decision support in AI models beyond six months to include the re-evaluation of therapy, which can significantly improve survival rates and patient outcomes.

       By adopting our Exclusive A.I. Mortality Model, healthcare providers, patients, and payors can experience the benefits of advanced, predictive analytics, leading to improved care delivery, better patient outcomes, and more efficient use of resources.